Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
www.cam-cancer.org
Incidence of severe hypoglycemia was 1% b Hypoglycemia was more frequent when RYBELSUS was used in combination with insulin secretagogues (eg, sulfonylurea) or insulin - Patients may require a lower dose of the secretagogue or insulin to reduce the risk of hypoglycemia in this setting A cardiovascular outcomes trial (CVOT) compared RYBELSUS added to standard of care vs placebo added to standard of care Primary endpoint was the time to first occurrence of a 3-part composite outcome of major adverse cardiovascular events (MACE), which included cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke The total number of primary component MACE endpoints was 137 (61 [3.8%] with RYBELSUS and 76 [4.8%] with placebo) CV=cardiovascular
Injection Site Reactions: Many GLP-1 medications are administered via subcutaneous injection, which can lead to injection site reactions such as redness, itching, or swelling
Prevention of chronic diseases like type 2 diabetes and heart disease could lead to substantial savings in healthcare costs
To view or add a comment, sign in A recent cohort study (not an RCT) found that semaglutide decreased the risk of psychiatric illness
These studizes collectively suggest that GLP-1RA treatment not only mitigates neurodegeneration but also ameliorates early-stage microvascular damage
